Trial Profile
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Ruxolitinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Folinic acid; Folinic acid; Mercaptopurine; Mesna; Methotrexate; Methotrexate; Methylprednisolone; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 28 Apr 2022 Status changed from completed to discontinued.
- 22 Jan 2021 Status changed from active, no longer recruiting to completed.
- 23 Jun 2020 Planned End Date changed from 31 Jul 2024 to 31 Jul 2023.